24 March 2017
The Defence Science and Technology Group (DST Group) in collaboration with d3 Medicine, a Certara Company invite the sector to participate in an audit of Australia’s capability and capacity to support Medical Countermeasures (MCM) product research and development.
The rapidly changing global landscape and Australia’s unique global position highlight a need to be strategic about national MCM advanced development and manufacturing requirements. With the recent announcement of the Defence Department’s Next Generation Technology Fund (NGTF), Australia has an opportunity to strengthen its MCM preparedness.
Results of the 2012 survey, highlighting internationally networked medical technology, biotechnology and pharmaceutical sector with pockets of MCM development excellence, leveraged $7 million in funding to support a number of collaborative projects and provided evidence for MCM products to be included in the NGTF.
The 2017 audit now seeks to understand how the medical technology, biotechnology and pharmaceutical sector has changed since 2012. It will determine where MCM assets, capabilities and capacities lie, helping to shape an MCM Business Plan under the NGTF.
The audit closes on Monday 10 April 2017.